Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This study will determine the effectiveness of oral risperidone versus long-acting injectable
risperidone in treating people with first-episode schizophrenia.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, Los Angeles
Collaborators:
Janssen Scientific Affairs, LLC National Institute of Mental Health (NIMH) Ortho-McNeil Janssen Scientific Affairs, LLC